Search

Glenn E Croston

from San Diego, CA
Age ~58
Get Report
Also known as:
Glenn Croston, Glenn Ttee, Glenn Roston, Clen Croston, Glen Corston, Croston Glenn
7882 Camino Tranquilo, San Diego, CA 92122
Related to:
Croston Gaia, 28Guadalupe L Petrone, 58
Connected to:
Alan R Croston, 63Brian S Croston, 51Charles D Croston, 76Jim T Croston, 64Philip A Croston, 28Robert L Crosty, 65Art H Croswell, 64Brian D Croswell, 41Charles S Croswell, 54Danielle R Croswell, 31

Glenn Croston Phones & Addresses

  • 7882 Camino Tranquilo, San Diego, CA 92122
  • 1269 Law St, San Diego, CA 92109
  • 5338 Middleton Rd, San Diego, CA 92109 (858) 273-0044 (858) 273-7244
  • San Francisco, CA

Work

Company: Gifts from the train station Sep 2011 Position: Author

Education

Degree: Ph.D. School / High School: University of California, San Diego 1988 to 1993 Specialities: Biochemistry

Skills

Sustainability • Strategic Planning • Project Management • Public Speaking • New Business Development • Research • Business Strategy

Interests

Writing, sustainability, green businesse...

Industries

Research

Resumes

Resumes

Glenn Croston Photo 1

Author Of "The Real Story Of Risk"

View page
Position:
Author at Gifts from the Train Station, Author at "The Real Story of Risk", Author at 75 Green Businesses, Founder at Starting Up Green, Director of Drug Discovery Pharmacology at Ferring Research Institute
Location:
Greater San Diego Area
Industry:
Research
Work:
Gifts from the Train Station since Sep 2011
Author
"The Real Story of Risk" - San Diego since May 2010
Author
75 Green Businesses since Jan 2008
Author
Starting Up Green since Jan 2008
Founder
Ferring Research Institute since May 2002
Director of Drug Discovery Pharmacology
Education:
University of California, San Diego 1988 - 1993
Ph.D., Biochemistry University of California, Davis 1982 - 1986
B.S., Biology
Skills:
Sustainability
Strategic Planning
Project Management
Public Speaking
New Business Development
Research
Business Strategy
Interests:
Writing, sustainability, green businesses, corporate social responsibility, the greater good, life, biology, behavioral economics, second chances, risk perception

Business Records

Name / Title
Company / Classification
Phones & Addresses
Glenn E. Croston
M
Starting Up Green
Nonclassifiable Establishments
PO Box 910133, San Diego, CA 92191
5338 Middleton Rd, San Diego, CA 92109

Publications

Isbn (Books And Publications)

Sat II: Biology E/m 2000

View page
Author

Glenn E. Croston

ISBN #

0684865173

Kaplan Ap Biology

View page
Author

Glenn E. Croston

ISBN #

0684873273

Sat II Biology E/m 2002-2003

View page
Author

Glenn E. Croston

ISBN #

0743232968

Kaplan Sat II: Biology E/m 2004-2005

View page
Author

Glenn E. Croston

ISBN #

0743251903

Kaplan SAT Subject Test: Biology E/M 2005-2006

View page
Author

Glenn E. Croston

ISBN #

0743265300

Us Patents

Azacyclic Compounds

View page
US Patent:
6756393, Jun 29, 2004
Filed:
Apr 7, 2003
Appl. No.:
10/409782
Inventors:
Carl-Magnus A. Andersson - Glostrup, DK
Glenn Croston - San Diego CA
Eva L. Hansen - Glostrup, DK
Allan Kjaersgaard Uldam - Glostrup, DK
Assignee:
Acadia Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K 3144
US Classification:
514352, 514183, 514357, 514358, 546244, 546246, 546248
Abstract:
Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.

Azacyclic Compounds

View page
US Patent:
6815458, Nov 9, 2004
Filed:
Mar 6, 2001
Appl. No.:
09/800096
Inventors:
Carl-Magnus A. Andersson - Glostrup, DK
Glenn Croston - San Diego CA
Eva Louise Hansen - Glostrup, DK
Allan Kjaersgaard Uldam - Glostrup, DK
Assignee:
Acadia Pharmaceuticals, Inc - San Diego CA
International Classification:
A61K 3144
US Classification:
514352, 514357, 514358, 546244, 546246, 546248
Abstract:
Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.

Azacyclic Compounds

View page
US Patent:
20050014757, Jan 20, 2005
Filed:
Mar 16, 2004
Appl. No.:
10/802970
Inventors:
Carl-Magnus Andersson - Glostrup, DK
Glenn Croston - San Diego CA, US
E.L. Hansen - Glostrup, DK
Allan Uldam - Glostrup, DK
International Classification:
A61K031/50
US Classification:
514248000, 514249000
Abstract:
Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is adminstered to a patient in need of such treatment.

Azacyclic Compounds

View page
US Patent:
20060194778, Aug 31, 2006
Filed:
May 3, 2006
Appl. No.:
11/417790
Inventors:
Carl-Magnus Andersson - Glostrup, DK
Glenn Croston - San Diego CA, US
E. Hansen - Glostrup, DK
Allan Uldam - Glostrup, DK
International Classification:
C07D 451/06
C07D 211/26
A61K 31/445
US Classification:
514210010, 514304000, 514317000, 546129000, 546229000, 548950000
Abstract:
Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.

Azacyclic Compounds

View page
US Patent:
20060194834, Aug 31, 2006
Filed:
May 3, 2006
Appl. No.:
11/417782
Inventors:
Carl-Magnus Andersson - Glostrup, DK
Glenn Croston - San Diego CA, US
E. Hansen - Glostrup, DK
Allan Uldam - Glostrup, DK
International Classification:
A61K 31/46
C07D 451/02
C07D 211/26
A61K 31/445
US Classification:
514304000, 514317000, 546124000, 546229000
Abstract:
Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.

Azacyclic Compounds

View page
US Patent:
20090186921, Jul 23, 2009
Filed:
Jan 16, 2009
Appl. No.:
12/355737
Inventors:
Carl-Magnus A. Andersson - Hjarup, SE
Glenn Croston - San Diego CA, US
E. L. Hansen - Hojby, DK
Allan Kjaersgaard Uldam - Ballerup, DK
Assignee:
ACADIA PHARMACEUTICALS, INC. - San Diego CA
International Classification:
A61K 31/445
C07D 211/26
C07K 14/705
A01N 1/00
A61P 25/00
US Classification:
514331, 546231, 530409, 435 2
Abstract:
Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.

Methods Of Treatment Using Selective 5-Ht2A Inverse Agonists

View page
US Patent:
20110301191, Dec 8, 2011
Filed:
Mar 21, 2011
Appl. No.:
13/053079
Inventors:
Carl-Magnus A. ANDERSSON - Glostrup, DK
Glenn Croston - San Diego CA, US
E.L. Hansen - Glostrup, DK
Allan Kjaersgaard Uldam - Glostrup, DK
International Classification:
A61K 31/4468
A61K 31/454
A61P 25/00
A61K 31/46
A61P 25/18
A61P 25/24
A61K 31/4535
A61K 31/4525
US Classification:
514304, 514329, 514326, 514322
Abstract:
Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.

Modulators Of Ob Gene And Screening Methods Therefor

View page
US Patent:
60689765, May 30, 2000
Filed:
Mar 19, 1996
Appl. No.:
8/618100
Inventors:
Michael R. Briggs - Downingtown PA
Johan Auwerx - Millionfosse, FR
Piet de Vos - Zingem, BE
Bart Staels - Kraainem, BE
Glenn E. Croston - San Diego CA
Stephen G. Miller - San Diego CA
Assignee:
Ligand Pharmaceuticals Incorporated - San Diego CA
International Classification:
C12Q 168
US Classification:
435 6
Abstract:
This invention relates to the isolation and cloning of the promoter and other control regions of a human ob gene. It provides a method for identifying and screening for agents useful for the treatment of diseases and pathological conditions affected by the level of expression of an ob gene. These agents interact directly or indirectly with the promoter or other control regions of the ob gene. A PPAR. gamma. agonist, BRL49653, has been identified to be useful in treating anorexia, cachexia, and other diseases characterized by insufficient food intake or body weight loss. Modulators of ob gene expression may be used to treat other diseases such as obesity, diabetes, hypertension, cardiovascular diseases and infertility.
Control profile
Glenn E Croston from San Diego, CA, age ~58 Get Report